TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16983741

Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy (25 Gy in five fractions of 5 Gy)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Preoperative conventionally fractionated chemoradiation (50.4 Gy in 28 fractions of 1.8 Gy, bolus 5-fluorouracil and leucovorin)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy
Number of subjects: 312

Group type: COMPARATOR
Intervention: Preoperative conventionally fractionated chemoradiation
Number of subjects: 312
Study: 14524058

Group type: EXPERIMENTAL
Intervention: Evidence-based guidelines implemented in Südwürttemberg after 6 months.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control cohort (Südbaden) without the new guidelines.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Antithrombotic treatments (various types).
Number of subjects: 400
Study: 10937402

Group type: EXPERIMENTAL
Intervention: Home hazard reduction program
Number of subjects: 530
Study: 8929605

Group type: EXPERIMENTAL
Intervention: Beta-blockade
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study: 1569294

Group type: EXPERIMENTAL
Intervention: Methionyl growth hormone (met‐GH) infusion (160 ng/kg/min lasting 180 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acipimox sustained release (ACX-SR) administered at 21:30 h and 09:30 h
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2866257

Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg t.i.d. on day 1, 10 mg b.i.d. on day 2, 10 mg o.d. for the remainder of the study)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 65
Study: 31634003

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of Hyaluronic Acid (HA) 1 week before the marathon
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal Saline (NS) control
Number of subjects: 20
Study: 30680396

Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin (PRF) combined with Bio‐oss
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flap surgery
Number of subjects: 30
Study: 26829000

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sedentary attention control program
Number of subjects: 35
Study: 24828079

Group type: EXPERIMENTAL
Intervention: Citalopram (antidepressant, selective serotonin reuptake inhibitor)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 22723318

Group type: EXPERIMENTAL
Intervention: AZD6370 (300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AZD1656 (80 mg) plus insulin (1 mU/kg · min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insulin infusion (0.8 mU/kg · min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insulin alone (1 mU/kg · min)
Number of subjects: 12
Study: 20585110

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 534
Study: 17253376

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 24
Study: 15380907

Group type: EXPERIMENTAL
Intervention: 250 kcal, 20 g protein supplement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 250 kcal, 3.5 g protein supplement
Number of subjects: 12

Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 12
Study: 11472706

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niacin 3,000 mg daily for 12 weeks
Number of subjects: 0
Study: 10399514

Group type: EXPERIMENTAL
Intervention: Softened endotracheal tube (heated in warm water)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Unsoftened endotracheal tube (intact)
Number of subjects: 62
Study: 7851059

Group type: COMPARATOR
Intervention: Complete bed rest for 10 hours after ingestion of the maintenance dose of digoxin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal daily activity
Number of subjects: 10
Study: 3132910

Group type: EXPERIMENTAL
Intervention: Two-day cathartic/enema preparation with oral administration of erythromycin and neomycin
Number of subjects: 593

Group type: COMPARATOR
Intervention: Orthograde lavage preparation with oral administration of metronidazole and neomycin
Number of subjects: 593
Study: 31473126

Group type: EXPERIMENTAL
Intervention: Light-emitting diode phototherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluorescent tube phototherapy
Number of subjects: 32
Study: 29529614

Group type: EXPERIMENTAL
Intervention: preopPTEd (one‐on‐one preoperative physical therapy education session and access to a web‐based microsite)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: preopPTEd
Number of subjects: 126
Study: 26493036

Group type: EXPERIMENTAL
Intervention: PCCC (Posterior Continuous Curvilinear Capsulorhexis)
Number of subjects: 20

Group type: COMPARATOR
Intervention: NCCC (No Continuous Curvilinear Capsulorhexis)
Number of subjects: 20
Study: 25642826

Group type: EXPERIMENTAL
Intervention: Dancing program
Number of subjects: 35

Group type: COMPARATOR
Intervention: Health-related exercise group
Number of subjects: 35
Study: 24158878

Group type: EXPERIMENTAL
Intervention: Carbetocin 20-100 μg iv
Number of subjects: 120
Study: 21918213

Group type: EXPERIMENTAL
Intervention: Solid food introduction at ≤ 13 weeks
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Solid food introduction at 14-17 weeks
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Solid food introduction at 18-21 weeks
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Solid food introduction at ≥ 22 weeks
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Solid food introduction
Number of subjects: 1090
Study: 18520295

Group type: EXPERIMENTAL
Intervention: Vandetinib (ZD6474) at a dose of up to 300 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vandetinib administered concurrently with chemotherapy
Number of subjects: 0
Study: 17023869

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 303
Study: 12639245

Group type: EXPERIMENTAL
Intervention: HAART supplemented with interleukin 2 (IL-2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAART supplemented with Remune
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial HAART
Number of subjects: 0
Study: 15808378

Group type: EXPERIMENTAL
Intervention: Vaginal insert (10 mg over 12 h)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Cervical gel (0.5 mg, twice in 12 h)
Number of subjects: 144
Study: 10522767

Group type: EXPERIMENTAL
Intervention: Nursing intervention using Orem's self‐care theory, five 30‐min sessions once a week during treatment and two follow-up sessions after treatment.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no nursing intervention).
Number of subjects: 67
Study: 8527016

Group type: EXPERIMENTAL
Intervention: Paediatric ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1981020

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 15
Study: 7017017

Group type: EXPERIMENTAL
Intervention: 100 mg of doxycycline per dose, taken biweekly for three weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo, taken biweekly for three weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 100 mg of doxycycline per dose
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31304892

Group type: EXPERIMENTAL
Intervention: Reversed stoma
Number of subjects: 487

Group type: COMPARATOR
Intervention: No stoma (control)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Colorectal cancer survivors (both groups)
Number of subjects: 487
Study: 27852695

Group type: EXPERIMENTAL
Intervention: Methotrexate + Infliximab (M+I) (5 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Methotrexate + Placebo (M+P)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Infliximab therapy (after 54 weeks)
Number of subjects: 18
Study: 26399192

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Aphasia Therapy (CIAT), 4 hours/day for 10 consecutive business days (total 40 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 24
Study: 23422107

Group type: EXPERIMENTAL
Intervention: rhPTH (1-34) 20 µg daily for 18 months
Number of subjects: 453

Group type: COMPARATOR
Intervention: elcatonin 20 U weekly for 12 months
Number of subjects: 453
Study: 21561303

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with ropivacaine, ketorolac, and epinephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Femoral nerve block
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 40
Study: 19761938

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (cTnI) prototype assay
Number of subjects: 2045
Study: 17702701

Group type: EXPERIMENTAL
Intervention: Breathing-enhanced upper extremity exercises
Number of subjects: 40
Study: 14749206

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/day for 24 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11384826

Group type: EXPERIMENTAL
Intervention: 1-2h in-office training program and/or self-study workbook
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 282
Study: 9987640

Group type: EXPERIMENTAL
Intervention: Acute AF in dogs (n = 5)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Chronic lone AF in patients (n = 7)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control patients (CTL, n = 10)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: AFDCM patients (n = 5)
Number of subjects: 17
Study: 8091041

Group type: EXPERIMENTAL
Intervention: Alternative treatments for rheumatoid arthritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health effects of air pollution
Number of subjects: 0
Study: 3041829

Group type: EXPERIMENTAL
Intervention: 36 X 10(6) units of recombinant interferon alpha‐2a per day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 68 X 10(6) units of recombinant interferon alpha‐2a per day
Number of subjects: 48
Study: 31055579

Group type: EXPERIMENTAL
Intervention: Creative Dance (CD)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Stretching (ST)
Number of subjects: 82
Study: 27878847

Group type: EXPERIMENTAL
Intervention: Supportive programme educating on implementation, strategies, goals, project management and leadership
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard implementation plan supplementary to the guideline
Number of subjects: 8
Study: 25880826

Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 23778767

Group type: EXPERIMENTAL
Intervention: Nonspecific mandibular mobilization (NMM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 21355716

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) Regular Human Insulin (RHI)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) Insulin Lispro (IL)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) Insulin Lispro (IL) and Regular Human Insulin (RHI)
Number of subjects: 29
Study: 20072737

Group type: EXPERIMENTAL
Intervention: Platform-switched implants
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional implants
Number of subjects: 10
Study: 20690287

Group type: EXPERIMENTAL
Intervention: Teacher instructions alone (E1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer education alone (E2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of teacher instruction and peer education (E3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study: 15105040

Group type: EXPERIMENTAL
Intervention: Fresh apples
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Processed applesauce
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study: 11973101

Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine 0.5%
Number of subjects: 51

Group type: COMPARATOR
Intervention: Topical diclofenac sodium 0.1%
Number of subjects: 51
Study: 9593358

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets (ITBN)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control (no ITBN)
Number of subjects: 503
Study: 8541750

Group type: EXPERIMENTAL
Intervention: Exciting video
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pleasant video
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amusing video
Number of subjects: 12

Group type: COMPARATOR
Intervention: No video
Number of subjects: 12
Study: 2228349

Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytically oriented group psychotherapy (STG)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Wait list (Control)
Number of subjects: 79
Study: 510179

Group type: EXPERIMENTAL
Intervention: Ethanol, 0.8 ml/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Meperidine, 100 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31501069

Group type: EXPERIMENTAL
Intervention: Cream-type adhesive
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Powder-type adhesive
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 200
Study: 31253216

Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation (PFNA)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 114
Study: 27397024

Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total laryngectomy
Number of subjects: 0
Study: 25735992

Group type: EXPERIMENTAL
Intervention: 150 mg JNJ-40411813
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 mg JNJ-40411813
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 150-225 mg JNJ-40411813
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 500 mg JNJ-40411813
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24077770

Group type: EXPERIMENTAL
Intervention: Training with immediate performance feedback
Number of subjects: 155

Group type: COMPARATOR
Intervention: Training with no performance feedback
Number of subjects: 155
Study: 22290001

Group type: EXPERIMENTAL
Intervention: 200 µg NTG plus 3 mg/kg 2% lidocaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 300 µg NTG plus 3 mg/kg 2% lidocaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 400 µg NTG plus 3 mg/kg 2% lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3 mg/kg 2% lidocaine diluted with saline (Control Group LS)
Number of subjects: 100
Study: 19653788

Group type: EXPERIMENTAL
Intervention: Medication Contingencies (MC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Voucher Contingency (VC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 120
Study: 16409324

Group type: EXPERIMENTAL
Intervention: Aqueous 17% (w/v) ethylenediaminetetraacetic acid rinse for 2 or 10 min followed by a 2% Patent Blue dye solution for 2 or 10 min
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tap water rinse for 2 or 10 min followed by a 2% Patent Blue dye solution for 2 or 10 min
Number of subjects: 80
Study: 11423841

Group type: EXPERIMENTAL
Intervention: Topical 20% aminolevulinic acid hydrochloride (ALA) with optimal light dose of 10 J/cm²
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle treatment with light
Number of subjects: 36
Study: 9015997

Group type: EXPERIMENTAL
Intervention: Paediatric diabetes specialist nurse intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care (before intervention)
Number of subjects: 56
Study: 8278621

Group type: EXPERIMENTAL
Intervention: lipo‐PGE1 (10 micrograms/day)
Number of subjects: 364

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 364

Group type: COMPARATOR
Intervention: PGE1‐CD (40 micrograms/day)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: lipo‐PGE1
Number of subjects: 364

Group type: COMPARATOR
Intervention: PGE1‐CD
Number of subjects: 364
Study: 3318751

Group type: EXPERIMENTAL
Intervention: Corticosteroid tapering regimen of one week
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Corticosteroid tapering regimen of seven weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Patients requiring mechanical ventilation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Patients reporting more than two days of worse than usual dyspnea
Number of subjects: 43
Study: 31863044

Group type: EXPERIMENTAL
Intervention: Occlusal surface reduction on the treated tooth
Number of subjects: 44

Group type: COMPARATOR
Intervention: No occlusal surface reduction (Control)
Number of subjects: 44
Study: 30515481

Group type: EXPERIMENTAL
Intervention: Abutment group (received Multi-Unit Abutment, MUA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No-abutment group (did not receive intermediate abutments)
Number of subjects: 32
Study: 27016006

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0
Study: 25410507

Group type: EXPERIMENTAL
Intervention: Angular stable locking system
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional locking screws
Number of subjects: 142
Study: 22577172

Group type: EXPERIMENTAL
Intervention: 0.3 mg rhTSH (n = 42)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 86
Study: 20979754

Group type: EXPERIMENTAL
Intervention: Esmolol (1 mg/kg intravenously followed by 150 microg x kg(‐1) x min(‐1) intravenous infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study: 18270313

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Attention-control health promotion education
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 332
Study: 15465443

Group type: EXPERIMENTAL
Intervention: Real rTMS at 10 Hz (2000 pulses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Real rTMS at 0.5 Hz (600 pulses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single dose of l-dopa
Number of subjects: 12
Study: 11833926

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (6-month, twice a week)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 94
Study: 9893890

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 44

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 44
Study: 7979119

Group type: EXPERIMENTAL
Intervention: 5% EMLA cream (lidocaine and prilocaine), applied to the venepuncture site for at least 60 minutes.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo cream, applied to the venepuncture site for at least 60 minutes.
Number of subjects: 60
Study: 2481328

Group type: COMPARATOR
Intervention: MOPP/ABVD
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABVD plus radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 0

Group type: COMPARATOR
Intervention: MOPP plus radiotherapy
Number of subjects: 0
Study: 864062

Group type: EXPERIMENTAL
Intervention: client-centered family approach
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: eclectic-dynamic approach
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: behaviorally oriented short-term family systems approach
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: family systems approach
Number of subjects: 86

Group type: COMPARATOR
Intervention: no treatment controls
Number of subjects: 86

Group type: COMPARATOR
Intervention: alternative treatment conditions
Number of subjects: 86
Study: 30439609

Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 939
Study: 28328946

Group type: EXPERIMENTAL
Intervention: CareToy intervention (4-week program)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard Care (4-week program)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CareToy intervention (4-week program) after Standard Care
Number of subjects: 41
Study: 25687540

Group type: EXPERIMENTAL
Intervention: Topical capsaicin application
Number of subjects: 110

Group type: COMPARATOR
Intervention: Untreated skin (control)
Number of subjects: 110
Study: 23708138

Group type: EXPERIMENTAL
Intervention: Intraoperative three-dimensional imaging (3D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computer assisted surgery (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraoperative pedography (IP)
Number of subjects: 0
Study: 21569574

Group type: EXPERIMENTAL
Intervention: Neoadjuvant ADT for ≥10 months after PSA reached < 0.2 ng/ml
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Neoadjuvant ADT (median duration 9 months)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Neoadjuvant ADT (median duration 7.5 months)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Duration of neoadjuvant ADT from when PSA reached < 0.2 ng/ml to surgery
Number of subjects: 68
Study: 18394265

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 17140281

Group type: EXPERIMENTAL
Intervention: Oral ziprasidone 40-80 mg twice daily for acute illness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ziprasidone 20-80 mg twice daily for chronic schizophrenia or schizoaffective disorder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone for acute agitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone overall
Number of subjects: 0
Study: 12773358

Group type: EXPERIMENTAL
Intervention: Individually tailored intervention for HIV prevention
Number of subjects: 0
Study: 11382625

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 66

Group type: COMPARATOR
Intervention: Apraclonidine 0.5%
Number of subjects: 66
Study: 9402180

Group type: EXPERIMENTAL
Intervention: GEM 1,200 mg/m2 + VNR 25 mg/m2
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GEM 1,200 mg/m2 + VNR 20 mg/m2
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GEM 1,000 mg/m2 + VNR 25 mg/m2
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 31